JP2003521471A5 - - Google Patents

Download PDF

Info

Publication number
JP2003521471A5
JP2003521471A5 JP2000610471A JP2000610471A JP2003521471A5 JP 2003521471 A5 JP2003521471 A5 JP 2003521471A5 JP 2000610471 A JP2000610471 A JP 2000610471A JP 2000610471 A JP2000610471 A JP 2000610471A JP 2003521471 A5 JP2003521471 A5 JP 2003521471A5
Authority
JP
Japan
Prior art keywords
formula
alkyl
compound
described formulation
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000610471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003521471A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/008401 external-priority patent/WO2000061138A1/en
Publication of JP2003521471A publication Critical patent/JP2003521471A/ja
Publication of JP2003521471A5 publication Critical patent/JP2003521471A5/ja
Withdrawn legal-status Critical Current

Links

JP2000610471A 1999-04-08 2000-03-30 慢性神経変性疾患を処置することに有用な抗痙攣薬誘導体 Withdrawn JP2003521471A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12829799P 1999-04-08 1999-04-08
US60/128,297 1999-04-08
PCT/US2000/008401 WO2000061138A1 (en) 1999-04-08 2000-03-30 Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US09/538,815 US6583172B1 (en) 1999-04-08 2000-03-30 Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US09/538,815 2000-03-30

Publications (2)

Publication Number Publication Date
JP2003521471A JP2003521471A (ja) 2003-07-15
JP2003521471A5 true JP2003521471A5 (cg-RX-API-DMAC7.html) 2007-02-15

Family

ID=26826463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000610471A Withdrawn JP2003521471A (ja) 1999-04-08 2000-03-30 慢性神経変性疾患を処置することに有用な抗痙攣薬誘導体

Country Status (7)

Country Link
US (1) US6583172B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003521471A (cg-RX-API-DMAC7.html)
AU (1) AU782344C (cg-RX-API-DMAC7.html)
CA (1) CA2369095C (cg-RX-API-DMAC7.html)
MX (1) MXPA01010217A (cg-RX-API-DMAC7.html)
NZ (1) NZ514813A (cg-RX-API-DMAC7.html)
WO (1) WO2000061138A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12413A (en) * 2000-11-30 2004-09-30 Pfizer Prod Inc Combination of GABA agonists and aldose reductase inhibitors.
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
DE60219961T8 (de) * 2001-02-02 2008-04-17 Ortho-Mcneil Pharmaceutical, Inc. Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
JP2004331502A (ja) * 2001-06-18 2004-11-25 Ortho Mcneil Pharmaceut Inc 視神経細胞保護剤
WO2003020289A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
JP2005512965A (ja) * 2001-09-24 2005-05-12 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 不穏四肢症候群および定期的四肢運動障害の処置に有用な抗痙攣誘導体
JP4630665B2 (ja) * 2002-09-13 2011-02-09 モタック・ニューロサイエンス・リミテッド ２，３−ベンゾジアゼピンによる基底核関連運動障害の治療
CN100502856C (zh) * 2002-09-17 2009-06-24 默塔克神经科学有限公司 运动障碍的治疗
EP1815854A1 (en) * 2002-09-17 2007-08-08 Motac Neuroscience Limited Treatment of dyskenesia
CA2550459C (en) * 2003-12-18 2009-12-15 Biomas, Ltd. Tellurium derivatives for prevention and treatment of neurodegenerative processes
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
PE20060500A1 (es) * 2004-08-24 2006-07-13 Janssen Pharmaceutica Nv Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
CA2609185A1 (en) * 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20110244057A1 (en) * 2008-09-25 2011-10-06 Ehrenberg Bruce L Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
CA2179733C (en) * 1993-12-23 2007-03-27 Michael J. Costanzo Anticonvulsant pseudofructopyranose sulfamates
EP0809624B1 (en) * 1995-02-15 2001-08-29 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
AU3501697A (en) * 1996-06-28 1998-01-21 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
ATE294577T1 (de) * 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen

Similar Documents

Publication Publication Date Title
JP2003521471A5 (cg-RX-API-DMAC7.html)
JP2004505004A5 (cg-RX-API-DMAC7.html)
JP2002541199A5 (cg-RX-API-DMAC7.html)
JP2002510633A5 (cg-RX-API-DMAC7.html)
JP2002519425A5 (cg-RX-API-DMAC7.html)
CA2399208A1 (en) Nucleoside analogs with carboxamidine modified monocyclic base
JP2003500442A5 (cg-RX-API-DMAC7.html)
JP2003509349A5 (cg-RX-API-DMAC7.html)
KR890701562A (ko) 면역조절 아자스 피란류
JP2003501474A5 (cg-RX-API-DMAC7.html)
KR870009718A (ko) 경구용 산에 불안정한물질의 약제
JP2004509061A5 (cg-RX-API-DMAC7.html)
JP2002519318A5 (cg-RX-API-DMAC7.html)
JP2003528808A5 (cg-RX-API-DMAC7.html)
CA2401569A1 (en) Low dose entecavir formulation and use
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
JP2002528502A5 (cg-RX-API-DMAC7.html)
JP2904827B2 (ja) 不安および不安抑うつ障害の処置に有用な医薬組成物の調製へのトリフルオロメチルフェニルテトラヒドロピリジンの使用
KR970706792A (ko) 수불용성 캄프토테신의 지질 복합체의 동결 건조물(Lyophilizate of lipid complex of water insoluble camptothecins)
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
JP4298998B2 (ja) ピラノンプロテアーゼインヒビターの経口投与自己乳化製剤
WO2001010387A2 (en) Antiviral therapy use of p-glycoprotein modulators
JP2002536328A5 (cg-RX-API-DMAC7.html)
JP2001520994A5 (cg-RX-API-DMAC7.html)
JP2002544227A5 (cg-RX-API-DMAC7.html)